USPTO serial 79066961
ARK THERAPEUTICS
Reviewed by CopyMark Law Group
Reg. 3742666Status 404
- Filing date
- Status date
- Registration date
- Jan 26, 2010
- Examiner
- WIENER, MICHAEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ARK THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CYNTHIA C. WEBER
CYNTHIA C. WEBER SUGHRUE MION, PLLC2100 PENNSYLVANIA AVE NWWASHINGTON, DC 20037-3202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic protein preparations for use in science, scientific diagnostics and industry; diagnostic preparations of genes for use in science, scientific diagnostics and industry | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutics purposes namely for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes namely for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes namely to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes namely for increasing the efficiency of muscle cell energy production | SECTION 71 - CANCELLED | — |
| 010 | Boots and gloves for orthopaedic and medical purposes; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for socks, boots and gloves for medical purposes, namely, for the treatment of wounds and burns; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; parts and fittings for all the aforesaid goods | SECTION 71 - CANCELLED | — |
| 042 | Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumours, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; advisory services relating to the aforesaid services; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; provision of information relating to the above | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Ark Therapeutics Limited
- Other trademarks owned by Ark Therapeutics Limited
- Other trademarks owned by Ark Therapeutics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named ARK THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 11, 2019 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Oct 11, 2019 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jun 16, 2017 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| May 11, 2017 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| May 11, 2017 | INPC | INVALIDATION PROCESSED | — |
| May 2, 2017 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 2, 2016 | C71T | CANCELLED SECTION 71 | — |
| Feb 7, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 24, 2010 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 24, 2010 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 26, 2010 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 26, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 10, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 21, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 7, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 5, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 12, 2009 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Sep 12, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 12, 2009 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 12, 2009 | ALIE | ASSIGNED TO LIE | — |
| Sep 9, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 18, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 10, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 10, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 10, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 9, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 5, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 28, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 24, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 23, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |